Clinical Trial Update: The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating TA-65, a telomerase activator, for effects on insulin resistance, inflammation, and metabolic syndrome. The trial was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Metabolic Syndrome

Drugs mentioned

• TA-65 (telomerase activator TA-65)

Snippet

Sponsor: University of Connecticut | Conditions: Metabolic Syndrome, Insulin Resistance | Phase 1 | Status: TERMINATED